[123] Biosimilars or Biologics: What’s the difference?
According to Greek mythology, the Chimera was a fire-breathing hybrid creature composed of parts of more than one animal, usually depicted as a lion with the head of a goat protruding from its back. Recombinant DNA (rDNA) is DNA created in laboratories, combining genetic material from different organisms appropriately called chimeric DNA. The term “biologics” can refer to a wide range of … [Read more...]
Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review
This is a state of the science review produced at the request of the Insurance Corporation of British Columbia (ICBC) to assist in developing funding policy for insurance claims involving the use of herbal cannabis and pharmaceutical cannabinoids for post injury medical management. Section 1 of the report provides an overall framework for funding policy for ICBC and a summary of clinical trial … [Read more...]
Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study
Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, Quail J, Marra F, Ernst P, Bugden S, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Clinical Microbiology and Infection. 2019 https://doi.org/10.1016/j.cmi.2019.10.016 Abstract Objectives: The United States Food & Drug Administration released an advisory in 2016 that fluoroquinolones be … [Read more...]
Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study
Ernst P, Dahl M, Chateau D, Daneman N, Quail J, Sketris IS, Fisher A,Zhang J, Bugden S, on behalf of the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators International Journal of Chronic Obstructive Pulmonary Disease. 2019:14 2939–2946. https://doi.org/10.2147/COPD.S226324 Abstract Purpose: Fluoroquinolone antibiotics are associated with rare, but severe … [Read more...]
Comparison of cholinesterase inhibitor safety in real-world practice
Carney G, Bassett K, Wright JM, Maclure M, McGuire N, Dormuth CR Alzheimer's & Dementia: Translational Research & Clinical Interventions. Volume 5, 2019, Pages 732-739. https://doi.org/10.1016/j.trci.2019.09.011 Highlights Galantamine was associated with fewer adverse events than donepezil or rivastigmine. Galantamine users experienced longer independent living. The … [Read more...]
Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research
Carney, G, Maclure, M, Bassett, K, Taylor, S, Dormuth, CR Pharmacoepidemiol Drug Saf. 2019; 1– 9. https://doi.org/10.1002/pds.4926 Abstract Purpose To describe and implement a novel method of measuring comparative effectiveness using sequential episodes of pharmacotherapy as a proxy for treatment failure. Methods Retrospective cohort study using linked deidentified data from the British … [Read more...]
Dr. Joanna Moncrieff: Drug treatment for bipolar disorder and psychosis
Dr. Joanna Moncrieff MD gave this presentation on October 5th, 2019 in Vancouver, BC at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. Moncrieff is a Senior Academic and Practicing Psychiatrist at the Mental Health Unit, University College of London; she is the author of "Myth of the Chemical Cure" and … [Read more...]
Expectations & Realities: Can We Directly Apply the Evidence for Topical Analgesics?
Dr. Jamie Falk gave this presentation on October 5th, 2019 in Vancouver, BC as one of the keynote speakers at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. Falk is an Assistant Professor in the College of Pharmacy and a Clinical Pharmacist associated with the Department of Family Medicine at the … [Read more...]
[122] Twenty-Five Pearls from 25 years (part 2)
In this Letter, the second in a 2-part anniversary series, we present the remaining 12 “clinical pearls” found in Therapeutics Letters published between 2006 and 2018. The Therapeutics Initiative is celebrating its 25th anniversary this year, in part by highlighting some key conclusions from the 120 issues of the Therapeutics Letter published so far. 14: The majority of new drugs do NOT represent … [Read more...]
[121] Twenty-Five Pearls from 25 years (part 1)
The Therapeutics Initiative is celebrating its 25th anniversary this year, in part by highlighting key conclusions from the 120 issues of the Therapeutics Letter published so far. In this first of a 2-part series we present 13 “clinical pearls” found in Letters published between 1994 and 2005. 1: Thiazides are clearly the drug of first choice for the treatment of uncomplicated hypertension Drugs … [Read more...]
- 1
- 2
- 3
- …
- 25
- Next Page »
